Guangzhou, China

Guiwu Xiao

This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 2009.


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:

goldMedal1 out of 834,411 
Other
 patents

Years Active: 2009

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Guiwu Xiao

Introduction

Guiwu Xiao is a notable inventor based in Guangzhou, China. He has made significant contributions to the field of pharmaceuticals through his innovative work on o-pyridinequinone derivatives. His research focuses on the development of compounds that have the potential to inhibit COX-2 selectively, which is crucial for creating safe and effective medications.

Latest Patents

Guiwu Xiao holds 1 patent for his invention titled "O-pyridinequinone derivatives, the composition containing the derivatives, the process for preparation of the derivatives and the use of the derivatives." This patent describes the o-pyridinequinone disubstituted derivatives, which are designed to inhibit COX-2 without causing acute toxicities, making them suitable for pharmaceutical applications.

Career Highlights

Throughout his career, Guiwu Xiao has demonstrated a commitment to advancing pharmaceutical science. His work has led to the development of compounds that are not only effective but also safe for use in medical treatments. His innovative approach has garnered attention in the scientific community.

Collaborations

Guiwu Xiao has collaborated with notable colleagues, including Jun Wang and Lianquan Gu. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Guiwu Xiao's contributions to the field of pharmaceuticals through his innovative work on o-pyridinequinone derivatives highlight his role as a significant inventor. His research not only advances scientific knowledge but also has the potential to improve patient care through safer medications.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…